Abstract | BACKGROUND: METHODS: A systematic literature search in MEDLINE was performed, until December 2012. We included randomized clinical trials investigating the effect of ESAs in STEMI patients undergoing primary PCI, with ≥30 days of follow-up. The primary end point was a composite of all-cause mortality, myocardial infarction, and stent thrombosis after PCI. Secondary end point was all-cause mortality. RESULTS: Individual patient data were obtained from 10 of 11 trials, including 97.3% (1,242/1,277) of all patients randomized to control (n = 600) or to ESAs (n = 642). Baseline characteristics were well balanced between the treatment allocations. Mean follow-up time was 248 (±131) days. The primary end point occurred in 3.5% (20/577) in the control group and in 2.1% (13/610) in the ESA group (hazard ratio for ESAs, 0.63; 95% CI [0.31-1.27]; P = .20). Mortality occurred in 13 (2.3%) in the control group and 5 (0.8%) in the ESA group (hazard ratio for ESAs, 0.38; 95% CI [0.13-1.06]; P = .06). CONCLUSIONS:
|
Authors | Marieke L Fokkema, Peter van der Meer, Sunil V Rao, Anne M Belonje, Maurizio Ferrario, Hans L Hillege, Stuart D Katz, Erik Lipšic, Andrew J Ludman, Ilka Ott, Fabrice Prunier, Dong-Ju Choi, Ken Toba, Dirk J van Veldhuisen, Adriaan A Voors |
Journal | American heart journal
(Am Heart J)
Vol. 168
Issue 3
Pg. 354-362.e2
(Sep 2014)
ISSN: 1097-6744 [Electronic] United States |
PMID | 25173548
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Copyright | Copyright © 2014 Mosby, Inc. All rights reserved. |
Chemical References |
|
Topics |
- Hematinics
(pharmacology)
- Humans
- Myocardial Infarction
(mortality)
- Percutaneous Coronary Intervention
- Risk Assessment
- Thromboembolism
(epidemiology)
- Ventricular Function, Left
(drug effects)
|